BPCIA Questions Continue To Arise For Biosimilar Applicants
On June 12, 2017, the U.S. Supreme Court decided its first case under the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), Sandoz Inc. v. Amgen Inc. (No. 15-1039, 15-1195)....To view the full article, register now.
Already a subscriber? Click here to view full article